Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Earnings Data
Report Date
Dec 04, 2025Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1Last Year’s EPS
-0.91Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighting significant achievements such as the FDA approval and successful early launch of EKTERLY, strong patient and prescriber engagement, and positive regulatory progress in Europe. However, challenges remain with high operating expenses and potential reimbursement hurdles with certain insurers.Company Guidance
FDA Approval of EKTERLY
EKTERLY was approved by the FDA as the first and only oral on-demand therapy for acute HAE attacks in adults and pediatric patients aged 12 and older, marking a significant advancement in treatment options for HAE.
Strong Early U.S. Launch Metrics
EKTERLY's U.S. launch saw almost 5% of the entire U.S. HAE population submitting a prescription, indicating strong early demand and rapid uptake among patients and healthcare providers.
Positive European Regulatory Progress
Sebetralstat received a positive CHMP opinion in Europe, with a final decision expected in October, and was granted 10 years of market exclusivity, indicating strong potential for international market entry.
Revenue Generation
KalVista reported $1.4 million in net revenue from EKTERLY sales during the launch period, indicating initial financial success from the product launch.
Broad Patient and Prescriber Engagement
Over 460 patient start forms were received, and 253 unique prescribers were activated, showcasing broad interest and engagement from both patients and healthcare providers.
KALV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KALV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Sep 11, 2025 | $15.39 | $14.81 | -3.77% |
Jul 10, 2025 | $15.99 | $15.51 | -3.00% |
Mar 12, 2025 | $12.43 | $12.45 | +0.16% |
Dec 05, 2024 | $9.46 | $9.06 | -4.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does KalVista Pharmaceuticals (KALV) report earnings?
KalVista Pharmaceuticals (KALV) is schdueled to report earning on Dec 04, 2025, Before Open (Confirmed).
What is KalVista Pharmaceuticals (KALV) earnings time?
KalVista Pharmaceuticals (KALV) earnings time is at Dec 04, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KALV EPS forecast?
KALV EPS forecast for the fiscal quarter 2026 (Q2) is -1.